Zenas Biopharma Inc (ZBIO) Stock Price, Quote & News

Company Profile

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004,...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 271 2954

Website: zenasbio.com

Address:

852 Winter Street, Suite 250, Waltham, United States

AIIAAIIA_88 Aug. 19 at 6:47 PM

$ZBIO Heavy volume!

0 · Reply

chole1 Aug. 19 at 4:28 PM

$ZBIO lets see if Lonnie can repeat the TSRO play again, SAN / ROG / NOVN / NVO and PFE, even LC bios in desperate need of assets, some will be tricky given overlap

0 · Reply

fda_tracker Aug. 14 at 9:39 PM

$ZBIO New PDUFA Date 2027-05-27 Zenas BioPharma, Inc. Link: https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_ex99-1.htm Calendar: http://www.fdatracker.com/fda-calendar/

0 · Reply

AIIAAIIA_88 Aug. 13 at 1:43 PM

$ZBIO Short attack…. They need to do better communications. For one, pre-announce ER date. JMO

1 · Reply

AIIAAIIA_88 Aug. 12 at 12:37 PM

$ZBIO ER?

0 · Reply

mahaljs Aug. 7 at 6:44 AM

$ZBIO - going back to $40+ by year end

0 · Reply

laaarsas Aug. 2 at 10:05 AM

$ZBIO What is this run-up!!?

0 · Reply

desmondekici Jul. 17 at 6:36 PM

$ZBIO Short Squuze!!

0 · Reply

ajmrtxl Jul. 14 at 2:16 PM

$ZBIO 's latest squeeze play

0 · Reply

AIIAAIIA_88 Jul. 2 at 2:02 AM

$ZBIO This will be much much higher at the end of this year! JMO

0 · Reply

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-17T13:05:28.000Z - 2 days ago

Zenas BioPharma price target raised to $32 from $22 at Morgan Stanley

2026-08-17T08:02:50.000Z - 2 days ago

Zenas BioPharma reports Q2 EPS ($1.77), consensus (75c)

2026-08-17T08:01:33.000Z - 2 days ago

Zenas BioPharma CFO Jennifer Fox to transition out of role

2026-08-16T13:18:06.000Z - 3 days ago

Zenas BioPharma price target raised to $32 from $22 at Morgan Stanley

Aug 13, 2026, 8:00 AM EDT - 6 days ago

Zenas BioPharma Slides: Corporate presentation

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Zenas BioPharma Earnings release: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Zenas BioPharma Quarterly report: Q2 2026

Jun 15, 2026, 7:00 AM EDT - 2 months ago

Zenas BioPharma Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 11, 2026, 4:15 PM EDT - 2 months ago

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Jun 2, 2026, 7:05 PM EDT - 2 months ago

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

Jun 2, 2026, 7:00 AM EDT - 2 months ago

Zenas BioPharma Slides: Corporate presentation

2026-05-28T11:23:43.000Z - 2 months ago

Zenas BioPharma submits BLA to FDA for obexelimab

May 28, 2026, 7:05 AM EDT - 2 months ago

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

May 19, 2026, 7:05 AM EDT - 3 months ago

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

2026-05-14T16:21:52.000Z - 3 months ago

Zenas BioPharma price target raised to $22 from $21 at Morgan Stanley

2026-05-14T09:57:16.000Z - 3 months ago

Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma

May 13, 2026, 7:00 AM EDT - 3 months ago

Zenas BioPharma Slides: Corporate presentation

2026-05-13T10:59:07.000Z - 3 months ago

Zenas BioPharma doses first patient in Phase 1 clinical trial of ZB021

May 13, 2026, 6:50 AM EDT - 3 months ago

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

2026-05-13T10:15:57.000Z - 3 months ago

Zenas BioPharma reports Q1 EPS ($1.46) vs. (80c) last year

May 13, 2026, 6:00 AM EDT - 3 months ago

Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 6:00 AM EDT - 3 months ago

Zenas BioPharma Earnings release: Q1 2026

May 13, 2026, 6:00 AM EDT - 3 months ago

Zenas BioPharma Quarterly report: Q1 2026

May 11, 2026, 8:00 AM EDT - 3 months ago

Zenas BioPharma Transcript: AGM 2026

2026-03-31T23:45:16.000Z - 5 months ago

Zenas BioPharma director buys $1.5M in common stock

2026-03-27T11:50:12.000Z - 5 months ago

Zenas BioPharma 5M share Spot Secondary priced at $20.00

Mar 27, 2026, 12:12 AM EDT - 5 months ago

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

2026-03-26T20:11:30.000Z - 5 months ago

Zenas announces common stock, convertible senior notes offerings

Mar 26, 2026, 4:01 PM EDT - 5 months ago

Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

2026-03-17T11:09:27.000Z - 5 months ago

Zenas BioPharma price target raised to $55 from $45 at Guggenheim

2026-03-17T10:20:49.000Z - 5 months ago

Zenas BioPharma price target raised to $21 from $19 at Morgan Stanley

2026-03-17T09:55:54.000Z - 5 months ago

Zenas BioPharma price target lowered to $41 from $43 at Citi

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Zenas BioPharma Proxy statement: Proxy Filing

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Zenas BioPharma Proxy statement: Proxy Filing

2026-03-16T11:06:10.000Z - 5 months ago

Zenas BioPharma reports Q4 EPS ($4.54) vs. ($1.26) last year

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Zenas BioPharma Annual report: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Zenas BioPharma Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Zenas BioPharma Slides: Corporate presentation

Feb 11, 2026, 1:30 PM EST - 6 months ago

Zenas BioPharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 9, 2026, 7:05 AM EST - 6 months ago

Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026

Feb 4, 2026, 7:05 AM EST - 7 months ago

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 22, 2026, 10:26 AM EST - 7 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 16, 2026, 4:15 PM EST - 7 months ago

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 5, 2026, 8:29 AM EST - 8 months ago

Zenas BioPharma's immune disorder drug meets main goal in late-stage trial

Jan 5, 2026, 8:00 AM EST - 8 months ago

Zenas BioPharma Transcript: Study Result

Jan 5, 2026, 8:00 AM EST - 8 months ago

Zenas BioPharma Press release: Study Result

Jan 5, 2026, 8:00 AM EST - 8 months ago

Zenas BioPharma Slides: Study Result

Jan 5, 2026, 7:05 AM EST - 8 months ago

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Dec 26, 2025, 7:00 AM EST - 8 months ago

Zenas BioPharma Slides: Corporate Presentation

Dec 15, 2025, 7:05 AM EST - 8 months ago

Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus

Dec 3, 2025, 7:55 AM EST - 9 months ago

Zenas BioPharma Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 18, 2025, 6:00 AM EST - 9 months ago

Zenas BioPharma Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 7:05 AM EST - 10 months ago

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 10 months ago

Zenas BioPharma Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Zenas BioPharma Quarterly report: Q3 2025

Nov 11, 2025, 7:05 AM EST - 10 months ago

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Oct 27, 2025, 7:05 AM EDT - 10 months ago

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Zenas BioPharma Transcript: Status Update

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Zenas BioPharma Press release: Status Update

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Zenas BioPharma Slides: Status Update

Oct 8, 2025, 6:04 AM EDT - 11 months ago

Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug

Oct 8, 2025, 5:00 AM EDT - 11 months ago

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

Sep 10, 2025, 7:45 AM EDT - 1 year ago

Zenas BioPharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 8:35 AM EDT - 1 year ago

Zenas BioPharma Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 1:00 PM EDT - 1 year ago

Zenas BioPharma Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 7:05 AM EDT - 1 year ago

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

RPRX

Aug 12, 2025, 7:05 AM EDT - 1 year ago

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Zenas BioPharma Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Zenas BioPharma Earnings release: Q2 2025

Jun 16, 2025, 3:44 AM EDT - 1 year ago

FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

Jun 11, 2025, 10:24 AM EDT - 1 year ago

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

AIIAAIIA_88 Aug. 19 at 6:47 PM

$ZBIO Heavy volume!

0 · Reply

chole1 Aug. 19 at 4:28 PM

$ZBIO lets see if Lonnie can repeat the TSRO play again, SAN / ROG / NOVN / NVO and PFE, even LC bios in desperate need of assets, some will be tricky given overlap

0 · Reply

fda_tracker Aug. 14 at 9:39 PM

$ZBIO New PDUFA Date 2027-05-27 Zenas BioPharma, Inc. Link: https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_ex99-1.htm Calendar: http://www.fdatracker.com/fda-calendar/

0 · Reply

AIIAAIIA_88 Aug. 13 at 1:43 PM

$ZBIO Short attack…. They need to do better communications. For one, pre-announce ER date. JMO

1 · Reply

AIIAAIIA_88 Aug. 12 at 12:37 PM

$ZBIO ER?

0 · Reply

mahaljs Aug. 7 at 6:44 AM

$ZBIO - going back to $40+ by year end

0 · Reply

laaarsas Aug. 2 at 10:05 AM

$ZBIO What is this run-up!!?

0 · Reply

desmondekici Jul. 17 at 6:36 PM

$ZBIO Short Squuze!!

0 · Reply

ajmrtxl Jul. 14 at 2:16 PM

$ZBIO 's latest squeeze play

0 · Reply

AIIAAIIA_88 Jul. 2 at 2:02 AM

$ZBIO This will be much much higher at the end of this year! JMO

0 · Reply

Jonita Jun. 29 at 3:38 PM

$ZBIO in in in

0 · Reply

PepCF Jun. 25 at 9:11 PM

$ZBIO Finally heading in the right direction

0 · Reply

knobs101 Jun. 25 at 5:44 PM

$ZBIO

0 · Reply

NomadEx Jun. 23 at 12:49 AM

$ZBIO

0 · Reply

LewisDaKat Jun. 21 at 12:01 PM

$ZBIO Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction. https://marketwirenews.com/stock/zbio/news/zenas-biopharma-s-ceo-purchased-60-000-company-share-8599998872235951.html?utm_source=stocktwits

0 · Reply

Dubbyy Jun. 20 at 8:56 PM

$ZBIO ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study https://www.zacks.com/stock/news/2812700/zbio-tanks-despite-positive-data-from-rare-autoimmune-diseases-study

0 · Reply

History101 Jun. 19 at 6:31 PM

$ZBIO 810 watching 6/19/2026

0 · Reply

PepCF Jun. 18 at 11:50 AM

$ZBIO Volume picking up on heavy insider buying. Consolidation looks strong around $18 after outstanding Phase 3 data and official BLA submission to the FDA. Strong support sitting at $17.00 - $17.50, looking to break through $20.00 resistance soon. FDA catalyst locked in

0 · Reply

Dubbyy Jun. 14 at 9:16 PM

$ZBIO Zenas BioPharma (ZBIO) Is Up 13.3% After Strong Obexelimab Phase 3 Data And FDA BLA Filing https://www.webullapp.com/news-detail/15053860608009216?audioNewsPlayedDuration=&theme=1&color=2&hl=en&android_sdk_int=36&canary-version=&_v=1&sp=1&statusBarHeightV2=25&isLite=false&wbFontSetting=small&wbFontUnit=29&wbFontSize=26&isSubsNews=false

0 · Reply

AIIAAIIA_88 Jun. 9 at 1:18 PM

$ZBIO What is everyone's expectation that this stock will start flying again? I mean, any catalyst this year or next? Asking for a friend. THX

2 · Reply

Merlintrader Jun. 5 at 1:21 PM

$ZBIO $ZBIO $VSTM $EDSA On the Move https://www.merlintrader.com/biotech-on-the-move-jun5/

0 · Reply

outlawinvestor1 Jun. 3 at 6:04 PM

$ZBIO $AMGN is playing defense in this press release - scared of obexelimab. https://www.amgen.com/newsroom/press-releases/2026/06/amgen-to-present-new-data-across-rare-autoimmune-and-inflammatory-diseases-at-eular-2026

0 · Reply

Market Cap	1.99B
Revenue (ttm)	10.00M
Net Income (ttm)	-377.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,777.40%
Debt to Equity Ratio	0.67

Volume	1,848,654
Avg Vol	862,738
Day's Range	N/A - N/A
Shares Out	65.18M
Stochastic %K	78%
Beta	-1.03
Analysts	Strong Sell
Price Target	$47.00